LENSAR Stock
LENSAR Inc
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Nicholas T. Curtis
- Employees
- 150
- Market cap
- $71 M
- IPO
- 02/10/2020
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the…
LENSAR stock: price history
1D
-3.8%
1W
-8.9%
1M
-18.1%
6M
-2.2%
YTD
-50.1%
1Y
-50.9%
2Y
+2.8%
5Y
-22.9%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~31% stronger price swings than usual
Ask the agents about LENSAR
Analyst assessment of LENSAR
PRICE TARGET LOW
US$11.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$13.00
0
STRONG BUY
2
BUY
1
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 20/08/2026
LENSAR stock metrics
P/E
4.57
P/B
4.79
EV/EBITDA
1.65
RETURN ON EQUITY
23.7%
NET MARGIN
21.4%
DEBT/EQUITY
0.16
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.0%
FLOAT SHARES
8,842,506
AVG. DAILY VOLUME (30D)
54,940
Insider transactions (SEC)
LINK WILLIAM J PHD
LINDSTROM RICHARD L MD
Winer Gary M
O'Farrell Elizabeth G.
WEISNER AIMEE S
Institutional holders
Comparable stocks
Frequently asked questions about LENSAR stock
What does LENSAR do?
LENSAR Inc is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Nicholas T. Curtis, the company employs around 150 people.
The IPO was on 02/10/2020; the stock trades on NASDAQ under the ticker LNSR.
What do analysts say about LENSAR stock?
3 analysts rate the stock, the consensus is Buy (as of 20/08/2026).
The average price target is US$12.00, ranging from US$11.00 to US$13.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does LENSAR report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does LENSAR pay a dividend?
No, LENSAR currently does not pay a dividend.
Which stocks are comparable to LENSAR?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get LENSAR stock analyzed?
Clicking "Analyze stock" lets five strategies assess LENSAR against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.